Ocular Therapeutix OCUL
Ocular Therapeutix, Inc · Nasdaq · Pharmaceutical Preparations
$7.29+8.48%close on Oct. 28, 2026 · volume 2.9M · Yahoo Finance
Price, last 47 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Oct. 8, 2026 | Todd Anderman Chief Legal Officer | Sold 10b5-1 plan | 11,984 | $7.29 | $87,363 |
| Oct. 2, 2026 | Peter Kaiser Chief Development Officer | Sold 10b5-1 plan | 9,990 | $7.05 | $70,430 |
| Oct. 2, 2026 | Jeffrey S. Heier Chief Scientific Officer | Sold 10b5-1 plan | 10,869 | $7.05 | $76,626 |
| Aug. 31, 2026 | Donald Notman Chief Operating Officer | Sold | 1,099 | $10.24 | $11,254 |
| Aug. 24, 2026 | Peter Kaiser Chief Development Officer | Sold 10b5-1 plan | 3,035 | $10.77 | $32,687 |
| Aug. 24, 2026 | Sanjay Nayak Chief Strategy Officer | Sold 10b5-1 plan | 1,897 | $10.78 | $20,450 |
| Aug. 24, 2026 | Jeffrey S. Heier Chief Scientific Officer | Sold 10b5-1 plan | 3,296 | $10.78 | $35,531 |
| Aug. 24, 2026 | Pravin Dugel See Remarks, director | Sold 10b5-1 plan | 21,649 | $10.77 | $233,160 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 12 →Departure/appointment of directors or officers
AI summary, unreviewedOcular Therapeutix Chief Strategy Officer Sanjay Nayak Resigns Effective October 16, 2026 to Join Private Company